532 results on '"Biological products industry -- Product development"'
Search Results
2. Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
3. Regen BioPharma, Inc. Expands Vision for Phase 1 Clinical Trial of HemaXelleratetm
4. Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836
5. PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax's Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government's Project NextGen
6. Sutro Biopharma Announces Initiation of the Registration-enabling REFRaME-P1 Trial with Luvelta for Pediatric Patients with CBF|GLIS AML
7. LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
8. Karolinska Development's portfolio company SVF Vaccines announces positive data from a phase 1 study of its universal Covid-19 vaccine
9. The Positive Topline Results From Phase III Study of UCB|Biogen's Dapirolizumab Pegol Brings a Ray of Hope in Systemic Lupus Erythematosus Therapeutic Space | DelveInsight
10. Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
11. Artax Biopharma to present first-in-class Nck modulator mechanism of action and Phase 1 data at the ACR Annual Meeting
12. Spine BioPharma, Inc. Unveils Completion Of Enrollment For Phase 3 Clinical Trial Of SB-01 To Address Chronic Low Back Pain
13. UCB and Biogen Announced Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
14. CD (Suzhou) Biopharma Announces FDA Clearance for Phase I Clinical Trial of CD-001
15. Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
16. Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
17. Gilead's Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada(r) In Second Pivotal Phase 3 Trial
18. GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1|2 Clinical Trial from the U.S. FDA
19. Vaxcyte Reports Positive Topline Data from Phase 1|2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine
20. FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)
21. AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema
22. Lytix Biopharma AS: Phase II preliminary results from skin cancer (BCC) clinical trial show an 86 percent overall reduction of tumor size, complete clearance in half of the patients and the potential to be utilized as a first-line therapy
23. Artax Biopharma completes patient recruitment in Phase 2a trial with first-in-class Nck modulator AX-158
24. WestGene advances clinical trials following dual IND approval for world's first EB virus-targeted mRNA therapeutic cancer vaccine
25. Artax Biopharma Raises $8 Million Ahead of Phase 2a Data Expected in Q4-2024
26. Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV111, a CD19 Directed in situ CAR T for Hematologic Malignancies
27. Ultimovacs ASA: Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024
28. OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer
29. Dynavax Initiates Phase 1|2 Study of Novel Shingles Vaccine Program
30. Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults
31. Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
32. Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity
33. Ultimovacs ASA: Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab
34. Kiromic BioPharma Reported Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
35. Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial
36. BioInvent Presents Promising Phase 1 Data for BI-1206 in Combination with KEYTRUDA(r) (pembrolizumab) in Patients with Solid Tumors at ASCO 2024
37. Kiromic BioPharma Adds UPMC As Fourth Deltacel-01 Clinical Trial Site
38. Be Biopharma Unveils New Preclinical Data for Novel B Cell Medicine for the Potential Treatment of Hypophosphatasia
39. IMUNON Reports Site Activation for IMNN-101 Phase 1 Vaccine Study
40. HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease
41. Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide
42. Lytix Biopharma AS: Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity
43. Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
44. Kiromic BioPharma reports favorable safety in Deltacel-01 clinical trial
45. Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort
46. Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
47. Kiromic BioPharma provides update on Deltacel-01 clinical trial results
48. BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA(r) (pembrolizumab)
49. Osivax Announced Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs
50. Blue Lake Biotechnology reports interim clinical data in children for its RSV vaccine candidate
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.